Optimal scan time for evaluation of parathyroid adenoma with [18F]-fluorocholine PET/CT

Rep, Sebastijan; Lezaic, Luka; Kocjan, Tomaz; Pfeifer, Marija; Sever, Mojca Jensterle; Simoncic, Urban; Tomse, Petra; Hocevar, Marko

doi:10.1515/raon-2015-0016

Abstract

Background. Parathyroid adenomas, the most common cause of primary hyperparathyroidism, are benign tumours which autonomously produce and secrete parathyroid hormone. [¹⁸F]-fluorocholine (FCH), PET marker of cellular proliferation, was recently demonstrated to accumulate in lesions representing enlarged parathyroid tissue; however, the optimal time to perform FCH PET/CT after FCH administration is not known. The aim of this study was to determine the optimal scan time of FCH PET/CT in patients with primary hyperparathyroidism.

Patients and methods. 43 patients with primary hyperparathyroidism were enrolled in this study. A triple-phase PET/CT imaging was performed five minutes, one and two hours after the administration of FCH. Regions of interest (ROI) were placed in lesions representing enlarged parathyroid tissue and thyroid tissue. Standardized uptake value (SUV_mean), retention index and lesion contrast for parathyroid and thyroid tissue were calculated.

Results. Accumulation of FCH was higher in lesions representing enlarged parathyroid tissue in comparison to the thyroid tissue with significantly higher SUV_mean in the second and in the third phase (p < 0.0001). Average retention index decreased significantly between the first and the second phase and increased significantly between the second and the third phase in lesions representing enlarged parathyroid tissue and decreased significantly over all three phases in thyroid tissue (p< 0.0001). The lesion contrast of lesions representing enlarged parathyroid tissue and thyroid tissue was significantly better in the second and the third phase compared to the first phase (p < 0.05).

Conclusions. According to the results the optimal scan time of FCH PET/CT for localization of lesions representing enlarged parathyroid tissue is one hour after administration of the FCH.

References

1. Lew JI, Solorzano CC. Surgical management of primary hyperparathyroidism: state of the art. Surg Clin North Am 2009; 89: 1205-25.10.1016/j.suc.2009.06.014
Search in Google Scholar
2. Wada Y, Kunimura T, Sato S, Hisayuki T, Sato M, Imataka H, et al. Proliferating potential and apoptosis in the development of secondary hyperparathyroidism: a study based on Ki-67 immunohistochemical staining and the terminal dUTP nick-end labeling assay. Ther Apher Dial 2008; 12: 319-28.10.1111/j.1744-9987.2008.00594.x
Search in Google Scholar
3. Yamaguchi S, Yachiku S, Morikawa M. Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism. J Clin Endocrinol Metab 1997; 82: 2681-8.10.1210/jc.82.8.2681
Search in Google Scholar
4. Allendorf J, DiGorgi M, Spanknebel K, Inabnet W, Chabot J, Logerfo P. 1112 consecutive bilateral neck explorations for primary hyperparathyroidism. World J Surg 2007; 31: 2075-80.10.1007/s00268-007-9068-5
Search in Google Scholar
5. Dowthwaite SA, Young JE, Pasternak JD, Yoo J. Surgical management of primary hyperparathyroidism. J Clin Densitom 2013; 16: 48-53.10.1016/j.jocd.2012.11.006
Search in Google Scholar
6. Wang CA. Surgical management of primary hyperparathyroidism. Curr Probl Surg 1985; 22: 1-50.10.1016/0011-3840(85)90019-X
Search in Google Scholar
7. Ruda JM, Hollenbeak CS, Stack BC, Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005; 132: 359-72.10.1016/j.otohns.2004.10.005
Search in Google Scholar
8. Miccoli P, Pinchera A, Cecchini G, Conte M, Bendinelli C, Vignali E, et al. Minimally invasive, video-assisted parathyroid surgery for primary hyperparathyroidism. J Endocrinol Invest 1997; 20: 429-30.10.1007/BF03347996
Search in Google Scholar
9. Goldstein RE, Blevins L, Delbeke D, Martin WH. Effect of minimally invasive radioguided parathyroidectomy on efficacy, length of stay, and costs in the management of primary hyperparathyroidism. Ann Surg 2000; 231: 732-42.10.1097/00000658-200005000-00014
Search in Google Scholar
10. Sosa JA, Udelsman R. Minimally invasive parathyroidectomy. Surg Oncol 2003; 12: 125-34.10.1016/S0960-7404(03)00041-0
Search in Google Scholar
11. Grant CS, Thompson G, Farley D, van Heerden J. Primary hyperparathyroidism surgical management since the introduction of minimally invasive parathyroidectomy: Mayo Clinic experience. Arch Surg 2005; 140: 472-479.10.1001/archsurg.140.5.47215897443
Search in Google Scholar
12. Coakley AJ, Kettle AG, Wells CP, O’Doherty MJ, Collins RE. 99mTc sestamibi-a new agent for parathyroid imaging. Nucl Med Commun 1989; 10: 791-4.10.1097/00006231-198911000-000032532313
Search in Google Scholar
13. Borley NR, Collins RE, O’Doherty M, Coakley A. Technetium-99m sestamibi parathyroid localization is accurate enough for scan-directed unilateral neck exploration. Br J Surg 1996; 83: 989-91.10.1002/bjs.18008307348813796
Search in Google Scholar
14. Carneiro-Pla DM, Solorzano CC, Irvin GL, 3rd. Consequences of targeted parathyroidectomy guided by localization studies without intraoperative parathyroid hormone monitoring. J Am Coll Surg 2006; 202: 715-22.10.1016/j.jamcollsurg.2006.02.00316648010
Search in Google Scholar
15. Lavely WC, Goetze S, Friedman KP, Leal JP, Zhang Z, Garret-Mayer E, et al. Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy. J Nucl Med 2007; 48: 1084-9.10.2967/jnumed.107.04042817574983
Search in Google Scholar
16. Berri RN, Lloyd LR. Detection of parathyroid adenoma in patients with primary hyperparathyroidism: the use of office-based ultrasound in preoperative localization. Am J Surg 2006; 191: 311-4.10.1016/j.amjsurg.2005.10.02716490537
Search in Google Scholar
17. Haber RS, Kim CK, Inabnet WB. Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism: comparison with (99m)technetium sestamibi scintigraphy. Clin Endocrinol (Oxf) 2002; 57: 241-9.10.1046/j.1365-2265.2002.01583.x12153604
Search in Google Scholar
18. Mapelli P, Busnardo E, Magnani P, Freschi M, Picchio M, Gianolli L, et al. Incidental finding of parathyroid adenoma with 11C-choline PET/CT. Clin Nucl Med 2012; 37: 593-5.10.1097/RLU.0b013e31824c5ffc22614195
Search in Google Scholar
19. Quak E, Lheureux S, Reznik Y, Bardet S, Aide N. F18-choline, a novel PET tracer for parathyroid adenoma? J Clin Endocrinol Metab 2013; 98: 3111-2.
Search in Google Scholar
20. Lezaic L, Rep S, Jensterle SM, Hocevar M, Fettich J. 18F-fluorocholine PET/CT for localization of hyper functioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging 2014; 41: 2083-9.10.1007/s00259-014-2837-025063039
Search in Google Scholar
21. Nakayama M, Okizaki A, Ishitoya S, Sakaguchi M, Sato J, Aburano T. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions. Ann Nucl Med 2013; 27: 163-9.10.1007/s12149-012-0669-1357555123188388
Search in Google Scholar
22. Cherry SR, Sorenson JA, Phelps ME. Physics in nuclear medicine. 4th edition Philadelphia: Elsevier/Saunders; 2012. p. 253-270.10.1016/B978-1-4160-5198-5.00016-2
Search in Google Scholar
23. Chien D, Jacene H. Imaging of parathyroid glands. Otolaryngol Clin North Am 2010; 43: 399-415.10.1016/j.otc.2010.01.00820510723
Search in Google Scholar
24. Hellman P, Ahlström H, Bergström M, Sundin A, Långström B, Westerberg G, et al. Positron emission tomography with 11C-methionine in hyperparathyroidism. Surgery 1994; 116: 974-81.
Search in Google Scholar
25. Otto D, Boerner AR, Hofmann M, Brunkhorst T, Meyer GJ, Petrich T, et al. Pre-operative localisation of hyperfunctional parathyroid tissue with 11C-methionine PET. Eur J Nucl Med Mol Imaging 2004; 31: 1405-12.10.1007/s00259-004-1610-115278308
Search in Google Scholar
26. Oksüz MO, Dittmann H, Wicke C, Müssig K, Bares R, Pfannenberg C, et al. Accuracy of parathyroid imaging: a comparison of planar scintigraphy, SPECT, SPECT/CT, and C-11 methionine PET for the detection of parathyroid adenomas and glandular hyperplasia. Diagn Interv Radiol 2011; 17: 297-307.
Search in Google Scholar
27. Giussani A, Janzen T, Uusijarvi-Lizana H, Tavola F, Zankl M, Sydoff M, et al. A compartmental model for biokinetics and dosimetry of 18F-choline in prostate cancer patients. J Nucl Med 2012; 53: 985-93.10.2967/jnumed.111.09940822570328
Search in Google Scholar
28. Tavola F, Janzen T, Giussani A, Facchinetti D, Veronese I, Uusijärvi-Lizana H, et al. Nonlinear compartmental model of 18F-choline. Nucl Med Biol 2012; 39: 261-8.10.1016/j.nucmedbio.2011.09.00222136887
Search in Google Scholar
29. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61: 110-7.
Search in Google Scholar

Optimal scan time for evaluation of parathyroid adenoma with [18F]-fluorocholine PET/CT

Abstract

Paradigm

My account